How should I adjust the diabetes treatment for an 89‑year‑old man with type 2 diabetes who is taking insulin glargine (Lantus) 12 U at bedtime, a fixed‑dose combination of glipizide (sulfonylurea) and metformin 500 mg twice daily, and empagliflozin 10 mg daily, and who has hyperglycemia (fasting glucose >200 mg/dL) and an A1c of 8.4%?

Treatment Adjustment for Uncontrolled Type 2 Diabetes in an 89-Year-Old

Increase the Lantus dose immediately using a systematic titration algorithm, discontinue the glipizide component of the glipizide-metformin combination to reduce hypoglycemia risk, and continue metformin and empagliflozin. 1

Immediate Insulin Titration

The current 12 units of Lantus is inadequate for this patient's glycemic control (blood glucose >200 mg/dL, A1c 8.4%). Increase the basal insulin dose by 2 units every 3 days until fasting plasma glucose reaches 100-130 mg/dL, or alternatively increase by 10-15% of the current dose once or twice weekly. 1 This evidence-based titration approach from the 2025 ADA Standards specifically addresses patients not meeting glycemic targets on basal insulin. 1

• Start by increasing to 14 units, then continue titrating upward every 3 days based on fasting glucose readings 1
• If hypoglycemia occurs (glucose <70 mg/dL), reduce the dose by 10-20% and identify the cause before resuming titration 1
• The patient will likely require 20-30 units or more to achieve adequate control, as the current dose is well below typical requirements 2, 3

Discontinue Sulfonylurea Component

Stop the glipizide portion of the glipizide-metformin combination immediately. 1 In an 89-year-old patient, sulfonylureas pose substantial hypoglycemia risk, particularly when combined with insulin therapy. 1 The 2023 ADA Standards for Older Adults explicitly recommend avoiding sulfonylureas in elderly patients on insulin due to severe hypoglycemia risk, which can cause falls, fractures, and cardiovascular events. 1

• Older adults have reduced awareness of hypoglycemic symptoms and higher risk of catastrophic complications from low blood glucose 1
• Glipizide adds minimal glycemic benefit when adequate basal insulin is provided 1
• Switch to metformin 500 mg twice daily alone (without glipizide) if gastrointestinal tolerance permits 1

Continue Metformin and Empagliflozin

Maintain metformin 500 mg twice daily and empagliflozin 10 mg daily. 1 These agents provide complementary mechanisms without increasing hypoglycemia risk and offer cardiovascular-renal protection particularly valuable in elderly patients. 1

• Metformin remains the foundation therapy unless contraindicated by renal function (eGFR <30 mL/min/1.73 m²) 1
• Empagliflozin provides cardiovascular and renal benefits independent of glucose lowering, which is especially important given this patient's age 1
• Monitor for genital mycotic infections with empagliflozin (6% incidence) and ensure adequate hydration 1

Glycemic Target Considerations for Age 89

Set a less stringent A1c target of <8.0% for this 89-year-old patient. 1 The 2023 ADA Standards for Older Adults recommend relaxed targets for elderly patients to minimize hypoglycemia risk while maintaining quality of life. 1

• Avoid pursuing A1c <7.0% in very elderly patients, as the risks outweigh benefits 1
• Focus on preventing symptomatic hyperglycemia and avoiding hypoglycemia rather than aggressive glucose lowering 1
• If the patient has multiple comorbidities or functional impairments, an A1c target of <8.5% may be more appropriate 1

Monitoring and Follow-up

Reassess glucose control and medication regimen every 3 months until A1c stabilizes at target, then every 6 months. 1

• Check fasting glucose daily during insulin titration to guide dose adjustments 1
• Assess for hypoglycemia symptoms at each visit, as elderly patients may have reduced awareness 1
• Monitor renal function periodically to ensure metformin and empagliflozin remain appropriate 1
• Consider vitamin B12 levels annually due to metformin's association with deficiency 1

Common Pitfalls to Avoid

The most critical error would be continuing the sulfonylurea while intensifying insulin—this combination dramatically increases severe hypoglycemia risk in elderly patients. 1 Another common mistake is under-titrating basal insulin due to fear of hypoglycemia; with proper sulfonylurea discontinuation and systematic titration, the insulin dose can be safely increased to achieve glycemic targets. 1 Finally, avoid therapeutic inertia—this patient's current regimen has clearly failed, and waiting longer without adjustment will only prolong hyperglycemia exposure and increase complication risk. 1